Concord Biotech is a leading API company with a proven track record. The company manufactures and exports APIs for a wide range of therapeutic areas. However, the company's international operations expose it to various complex risks," said Anubhuti Mishra, Equity Research Analyst at Swastika Investmart.Read more:
- Concord Biotech shares list at a healthy premium. What should investors do?- (The Economic Times)
- Concord Biotech share price extends gain after listing at 21% premium. Buy, sell or hold? -(Mint)
- Concord Biotech IPO Makes Solid Debut, Lists At Rs 900 Per Share On BSE -(Outlook)
- Concord Biotech lists at 21% premium over its issue price- (Business Standard)
- India’s Concord Biotech ends 27% higher in debut at $1 billion valuation -(The Print)
